Evidence map›Paper›PMID 34745552›Full record

ArticleChemical science2021

Nickel-catalyzed enantioselective 1,2-vinylboration of styrenes.

Yang Ye, Jiandong Liu, Bing Xu, Songwei Jiang, Renren Bai, Shijun Li, Tian Xie, Xiang-Yang Ye

Abstract read
In one paragraph

Article in Chemical science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yang YeSchool of Pharmacy, Hangzhou Normal University Hangzhou Zhejiang 311121 PR China yeyang0711@163.com xbs@hznu.edu.cn xyye@hznu.edu.cn.ORCID https://orcid.org/0000-0001-5279-8104
Jiandong LiuCenter for Supramolecular Chemistry and Catalysis, Department of Chemistry, Shanghai University Shanghai 200444 PR China.
Bing XuSchool of Pharmacy, Hangzhou Normal University Hangzhou Zhejiang 311121 PR China yeyang0711@163.com xbs@hznu.edu.cn xyye@hznu.edu.cn.
Songwei JiangSchool of Pharmacy, Hangzhou Normal University Hangzhou Zhejiang 311121 PR China yeyang0711@163.com xbs@hznu.edu.cn xyye@hznu.edu.cn.
Renren BaiSchool of Pharmacy, Hangzhou Normal University Hangzhou Zhejiang 311121 PR China yeyang0711@163.com xbs@hznu.edu.cn xyye@hznu.edu.cn.
Shijun LiCollege of Material, Chemistry and Chemical Engineering, Hangzhou Normal University Hangzhou Zhejiang 311121 PR China.ORCID https://orcid.org/0000-0003-1480-9292
Tian XieSchool of Pharmacy, Hangzhou Normal University Hangzhou Zhejiang 311121 PR China yeyang0711@163.com xbs@hznu.edu.cn xyye@hznu.edu.cn.
Xiang-Yang YeSchool of Pharmacy, Hangzhou Normal University Hangzhou Zhejiang 311121 PR China yeyang0711@163.com xbs@hznu.edu.cn xyye@hznu.edu.cn.ORCID https://orcid.org/0000-0003-3739-0930

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A novel nickel-catalyzed asymmetric 1,2-vinylboration reaction has been developed to afford benzylic alkenylboration products with high yields and excellent enantioselectivities by using a chiral bisoxazoline ligand. Under optimized conditions, a wide variety of chiral 2-boryl-1,1-arylvinylalkanes are efficiently prepared from readily available olefins and vinyl halides in the presence of bis(pinacolato)diboron as the boron source in a mild and easy-to-operate manner. This three-component cascade protocol furnishes exceptional chemo- and stereoselectivity, and its usefulness is illustrated by its application in asymmetric modifications of several structurally complex natural products and pharmaceuticals.

Identifiers

PMID34745552
PMCPMC8513998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.